Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.26 (
GSK
)
6,788
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Wnt family members are critical in developmental processes and have been shown to promote carcinogenesis when ectopically expressed in the mouse mammary gland. The gene expression pattern mediated by Wnt is pivotal for these diverse responses. The Wnt pathway has been conserved among different species. Genetic studies have shown that Wnt effects are mediated, at least in part, by beta-catenin, which regulates transcription of "downstream genes." Wnt stimulation inactivates glycogen-synthase kinase-3beta (GSK-3) with subsequent stabilization of beta-catenin, which after heterodimerizing with lymphocyte enhancer factor-1/T-cell factor cofactors stimulates transcription. To establish whether Wnt-stimulated transcription is mediated solely by beta-catenin, a comparison was made of gene expression profiles in response to Wnt-3, overexpression of beta-catenin, and inhibition of
GSK
-3. Infection of cells with Wnt-3 and inhibition of
GSK
-3 regulate a set of genes that include
cyclooxygenase-2
and periostin. Interestingly, overexpression of beta-catenin or reducing beta-catenin levels with antisense oligonucleotide transfection did not have any effect on
cyclooxygenase-2
or periostin expression, thereby defining a Wnt pathway, which cannot be mimicked by beta-catenin overexpression.
...
PMID:Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells. 1088 77
Ultraviolet B (UVB)-induced
cyclooxygenase-2
(
COX-2
) expression plays an important role in UVB tumor promotion. We examined whether Akt and glycogen synthase kinase 3beta (GSK-3beta), components of the phosphatidylinositol 3'-kinase pathway, are involved in UVB induction of
COX-2
transcription. UVB caused Akt phosphorylation at both Thr-308 and Ser-473 that was inhibited by LY294002, a phosphatidylinositol 3'-kinase inhibitor. LY294002 also decreased the expression of endogenous
COX-2
protein and a luciferase construct driven by
COX-2
promoter. Similarly, UVB caused phosphorylation of
GSK
-3beta (Ser-9) and presumably inactivation of
GSK
-3beta. Inhibition of
GSK
-3beta by lithium induced endogenous
COX-2
protein expression and
COX-2
promoter activity. Finally, overexpression of a dominant-negative Akt mutant or wild-type
GSK
-3beta suppressed UVB-mediated induction of
COX-2
promoter. These studies suggest that inactivation of
GSK
-3beta through activation of Akt plays an important role in the UVB induction of
COX-2
transcription.
...
PMID:Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. 1138 54
The survival of renal medullary interstitial cells (RMICs) requires their adaptation to rapid shifts in ambient tonicity normally occurring in the renal medulla. Previous studies determined that
cyclooxygenase-2
(COX 2) activation is critical for this adaptation. The present studies find that these adaptive mechanisms are dampened by the simultaneous activation of an apoptotic pathway linked to a glycogen synthase kinase 3beta (
GSK
3beta). Inhibition of
GSK
3 by LiCl or specific small molecule
GSK
inhibitors increased RMIC survival following hypertonic stress, and transduction of RMICs with a constitutively active
GSK
3beta (AdGSK 3betaA9) significantly increased apoptosis, consistent with a proapoptotic role of
GSK
3beta. Following
GSK
3beta inhibition, increased survival was accompanied by increased COX 2 expression and COX 2 reporter activity. In contrast,
GSK
3beta overexpression reduced COX 2 reporter activity. Importantly, enhanced RMIC survival produced by
GSK
3beta inhibition was completely dependent on COX 2 because it was abolished by a COX 2-specific inhibitor, SC58236. The signaling pathway by which
GSK
3beta suppresses COX 2 expression was then explored.
GSK
3beta inhibition increased both NFkappaB and beta-catenin activity associated with decreased IkappaB and increased beta-catenin levels. The increase in COX 2 following
GSK
3beta inhibition was entirely blocked by NFkappaB inhibition using mutant IkappaB adenovirus. However, adenoviral overexpression of beta-catenin did not increase COX 2 levels. These findings suggest that
GSK
3beta negatively regulates COX 2 expression and that
GSK
3beta inhibitors protect RMICs from hypertonic stress via induction of NFkappaB-COX 2-dependent pathway.
...
PMID:Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkappaB-driven cyclooxygenase-2-dependent survival pathway. 1460 40
beta-Catenin plays a dual role in cells: one at cell-cell junctions and one regulating gene transcription together with TCF (T-cell Factor) in the nucleus. Recently, a role for beta-catenin in osteoblast differentiation and gene expression has begun to be elucidated. Herein we investigated the effects of fluid shear stress (FSS) on beta-catenin signaling. FSS is a well-characterized anabolic stimulus for osteoblasts; however, the molecular mechanisms for the effects of this stimulation remain largely unknown. We found that 1 hour of laminar FSS (10 dynes/cm(2)) induced translocation of beta-catenin to the nucleus and activated a TCF-reporter gene. Analysis of upstream signals that may regulate beta-catenin signaling activity revealed two potential mechanisms for increased beta-catenin signaling. First, FSS induced a transient, but significant, increase in the phosphorylation of both glycogen synthase kinase 3beta (GSK-3beta) and Akt. Second, FSS reduced the levels of beta-catenin associated with N-cadherin, suggesting that less sequestration of beta-catenin by cadherins occurs in osteoblasts subjected to FSS. Functional analysts of potential genes regulated by beta-catenin signaling in osteoblasts revealed two novel observations. First, endogenous, nuclear beta-catenin purified from osteoblasts formed a complex with a TCF -binding element in the
cyclooxygenase-2
promoter, and, second, overexpression of either a constitutively active beta-catenin molecule or inhibition of
GSK
-3beta activity increased basal
cyclooxygenase-2
levels. Together, these data demonstrate for the first time that FSS modulates the activity of both
GSK
-3beta and beta-catenin and that these signaling molecules regulate
cyclooxygenase-2
expression in osteoblasts.
...
PMID:Fluid shear stress induces beta-catenin signaling in osteoblasts. 1559 96
Activation of activator protein-1 (AP-1) and increased expression of
cyclooxygenase-2
(
COX-2
) have been clearly shown to play a functional role in UVB-induced skin tumor promotion. In this study, we examined UVB-induced signal transduction pathways in SKH-1 mouse epidermis leading to increases in
COX-2
expression and AP-1 activity. We observed rapid increases in p38 mitogen-activated protein kinase (MAPK) signaling through activation of p38 MAPK and its downstream target, MAPK activated protein kinase-2. UVB also increased phosphatidylinositol 3-kinase (PI3K) signaling as observed through increases in AKT and
GSK
-3beta phosphorylation. Activation of the p38 MAPK and PI3K pathways results in the phosphorylation of cyclic AMP-responsive element binding protein, which was also observed in UVB-irradiated SKH-1 mice. Topical treatment with SB202190 (a specific inhibitor of p38 MAPK) or LY294002 (a specific inhibitor of PI3K) significantly decreased UVB-induced AP-1 activation by 84% and 68%, respectively, as well as
COX-2
expression. Our data show that in mouse epidermis, UVB activation of the p38 MAPK and PI3K pathways leads to AP-1 activation and
COX-2
expression.
...
PMID:Inhibition of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model. 1575 75
Celecoxib, a
cyclooxygenase-2
(
COX-2
) selective nonsteroidal anti-inflammatory drug, is a new anticarcinogenic agent. Its antitumor effects depend on the one hand on its
COX-2
-inhibiting potency, but on the other hand on
COX-2
-independent mechanisms, which until now have not been fully understood. Here, we investigated whether celecoxib has an impact on the APC/beta-catenin pathway, which has been shown to play a pivotal role in the development of various cancers, especially of the colon. After only 2 h of treatment of human Caco-2 colon carcinoma cells with 100 muM celecoxib, we observed a rapid translocation of beta-catenin from its predominant membrane localization to the cytoplasm. Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the
GSK
-3beta kinase was essential for this release. Furthermore, the cytosolic accumulation was accompanied by a rapid increase of beta-catenin in the nuclei, starting already 30 min after celecoxib treatment. The DNA binding activity of beta-catenin time dependently decreased 2 h after celecoxib treatment. After this cellular reorganization, we observed a caspase- and proteasome-dependent degradation of beta-catenin after 8 h of drug incubation. Celecoxib-induced beta-catenin degradation was also observed in various other tumor cell lines (HCT-116, MCF-7, and LNCAP) but was not seen after treatment of Caco-2 cells with either the anticarcinogenic nonsteroidal anti-inflammatory drug R-flurbiprofen or the highly
COX-2
-selective inhibitor rofecoxib. These findings indicate that the anticarcinogenic effects of celecoxib can be explained, at least partly, by an extensive degradation of beta-catenin in human colon carcinoma cells.
...
PMID:Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. 1594 92
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, which can lead to the development of liver cirrhosis and hepatocellular carcinoma. Recently, the activation of
cyclooxygenase-2
(
Cox-2
) has been implicated in the HCV-associated hepatocellular carcinoma. In this study, we focus on the signaling pathway leading to
Cox-2
activation induced by HCV gene expression. Here, we demonstrate that the HCV-induced reactive oxygen species and subsequent activation of NF-kappaB mediate the activation of
Cox-2
. The HCV-induced
Cox-2
was sensitive to antioxidant (pyrrolidine dithiocarbamate), Ca(2+) chelator (BAPTA-AM), and calpain inhibitor (N-acetyl-Leu-Leu-Met-H). The levels of prostaglandin E(2) (PGE(2)), the product of
Cox-2
activity, are increased in HCV-expressing cells. Furthermore, HCV-expressing cells treated with the inhibitors of
Cox-2
(celecoxib and NS-398) showed significant reduction in PGE(2) levels. We also observed the enhanced phosphorylation of Akt and its downstream substrates
glycogen synthase kinase-3beta
and proapoptotic Bad in the HCV replicon-expressing cells. These phosphorylation events were sensitive to inhibitors of
Cox-2
(celecoxib and NS-398) and phosphatidylinositol 3-kinase (LY294002). Our results also suggest a potential role of
Cox-2
and PGE(2) in HCV RNA replication. These studies provide insight into the mechanisms by which HCV induces intracellular events relevant to liver pathogenesis associated with viral infection.
...
PMID:Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. 3293 70
Glycogen-synthase kinase-3 (GSK-3) and extracellular signal-regulated kinase (ERK) are critical downstream signaling proteins for the PI3-kinase/Akt and Ras/Raf/MEK-1 pathway, respectively, and regulate diverse cellular processes including embryonic development, cell differentiation and apoptosis. Here, we show that inhibition of
GSK
-3 using
GSK
-3 inhibitors or RNA interference (RNAi) significantly induced the phosphorylation of ERK1/2 in human colon cancer cell lines HT29 and Caco-2. Pretreatment with the PKCdelta-selective inhibitor rottlerin or transfection with PKCdelta siRNA attenuated the phosphorylation of ERK1/2 induced by the
GSK
-3 inhibitor SB-216763 and, furthermore, treatment with SB-216763 or transfection with
GSK
-3alpha and
GSK
-3beta siRNA increased PKCdelta activity, thus identifying a role for PKCdelta in the induction of ERK1/2 phosphorylation by
GSK
-3 inhibition. Treatment with SB-216763 increased expression of
cyclooxygenase-2
(
COX-2
) and IL-8, which are downstream targets of ERK1/2 activation; this induction was abolished by MEK/ERK inhibition, suggesting
GSK
-3 inhibition induced
COX-2
and IL-8 through ERK1/2 activation. The transcriptional induction of
COX-2
and IL-8 by
GSK
-3 inhibition was further demonstrated by the increased
COX-2
and IL-8 promoter activity after SB-216763 treatment or transfection with
GSK
-3alpha or
GSK
-3beta siRNA. Importantly, our findings identify
GSK
-3, acting through PKCdelta, as a negative regulator of ERK1/2, thus revealing a novel crosstalk mechanism between these critical signaling pathways.
...
PMID:Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. 1627 84
Cyclooxygenase-2
(
COX-2
) expression is a marker of poor prognosis in gastric cancer patients, and its inhibition suppresses gastric tumorigenesis in experimental animal models. The mechanism that leads to
COX-2
overexpression in this tumor type is unknown. We have now shown that inhibition of phosphatidylinositol 3-kinase by LY294002 suppresses both basal and phorbol myristate acetate-induced
COX-2
expression in TMK-1 and MKN-28 gastric cancer cells. Furthermore, inhibition of
glycogen synthase kinase-3beta
(GSK-3beta) by SB415286 induced expression of
COX-2
mRNA and protein as well as the enzyme activity in the gastric cancer cells. The effect of SB415286 was confirmed by the use of two additional
GSK
-3beta inhibitors, lithium chloride and SB216763. SB415286 had a modest 1.6-fold stimulatory effect on a 2-kb
COX-2
promoter reporter construct, but more importantly, it was shown to block the decay of
COX-2
mRNA. In contrast to modulation of phosphatidylinositol 3-kinase/Akt/
GSK
-3beta pathway, inhibitors of mitogen-activated protein kinases (MEK 1/2, p38, JNK) or the mammalian target of rapamycin did not alter
COX-2
expression in gastric cancer cells. Our data show that inhibition of
GSK
-3beta stimulates
COX-2
expression in gastric cancer cells, which seems to be primarily facilitated via an increase in mRNA stability and to a lesser extent through enhanced transcription.
...
PMID:Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. 1637 52
Cyclooxygenase-2
(
COX-2
) induction and prostaglandin E(2) (PGE(2)) elevation have been reported to occur after cerebral ischemic insult. PGE(2) induces apoptosis through the PGE(2) EP2 receptor by a cAMP-dependent pathway. Glycogen synthase kinase-3 (GSK-3) affects many fundamental cellular functions. We examined whether
GSK
-3 is involved in PGE(2)-induced cell death by using
GSK
-3 inhibitors in rat cultured cortical neurons. Cells treated with 12.5 microM PGE(2) for 2 days shrank. The injured cells underwent chromatin condensation and nuclear fragmentation detected by staining with Hoechst33258, indicating apoptotic cell death. We assayed the effects of selective
GSK
-3 inhibitors SB216763 and alsteropaullone on PGE(2)-induced apoptosis. These inhibitors completely protected the cells from apoptosis induced by PGE(2). Moreover, dibutyryl cAMP (a cell permeable cAMP)-induced apoptosis was also prevented by alsteropaullone. In addition,
GSK
-3 inhibitors inhibited caspase-3 activation accompanied by PGE(2)-induced apoptosis. We showed in this report that PGE(2)-induced apoptosis is prevented by
GSK
-3 inhibitors, suggesting that PGE(2) induces caspase-dependent apoptosis mediated through
GSK
-3 activation in rat cultured cortical neurons.
...
PMID:Prevention of rat cortical neurons from prostaglandin E2-induced apoptosis by glycogen synthase kinase-3 inhibitors. 1650 98
1
2
3
4
5
Next >>